Defining the phenotype
Sarcopenia, formally defined in the European Working Group on Sarcopenia in Older People (EWGSOP2) 2018 consensus, refers to a progressive and generalised skeletal muscle disorder characterised by low muscle strength (measured by handgrip or chair-stand test), low muscle quantity or quality (measured by DXA, BIA, CT, or MRI), and in severe cases, low physical performance (gait speed, SPPB score). Obesity refers to excess adipose tissue mass relative to body composition norms.
Sarcopenic obesity is the co-occurrence of both — and it is clinically distinct from either in isolation. Individuals with sarcopenic obesity have worse metabolic outcomes, worse functional status, higher cardiovascular risk, higher mortality, and greater disability incidence than individuals with either sarcopenia alone or obesity alone. A 2020 meta-analysis by Tian and colleagues found that sarcopenic obesity was associated with a two-fold increase in mortality risk compared to normal-weight individuals with normal muscle mass.
The prevalence of sarcopenic obesity is increasing as the combination of aging populations and the obesity pandemic converge. Estimates vary depending on the diagnostic criteria used — there is no universal consensus on thresholds — but a 2022 review estimated prevalence at 5–10% of older adults in high-income countries, rising to 20% or above in specific high-risk populations (frail elderly, post-bariatric surgery patients, cancer survivors).
Why the phenotype perpetuates itself: the adipomyokine cycle
Sarcopenic obesity is not simply two coincidental problems. The two components interact in ways that amplify each other, creating a self-reinforcing cycle. Understanding this cycle matters for evaluating any intervention.
Adipose tissue — particularly visceral adipose tissue — is not metabolically inert. It is an active endocrine organ secreting adipokines including leptin, resistin, and TNF-α. In obesity, adipose tissue becomes inflamed (adipose tissue macrophage infiltration is a characteristic finding), and the secretome shifts toward pro-inflammatory adipokines. TNF-α and IL-6 from visceral fat reach systemic circulation and activate protein degradation pathways in skeletal muscle — specifically the ubiquitin-proteasome system via atrogin-1 and MuRF1 E3 ubiquitin ligases. This drives muscle catabolism.
Conversely, skeletal muscle is itself an endocrine organ, secreting myokines during contraction. The most important anti-obesity myokine is irisin, cleaved from the transmembrane protein FNDC5 during exercise. Irisin acts on white adipose tissue, promoting “browning” — increased expression of UCP1 (uncoupling protein 1), which dissipates energy as heat rather than synthesising ATP. In sarcopenia, reduced muscle mass means reduced irisin secretion, reduced adipose browning, and therefore reduced basal energy expenditure — which favours further fat accumulation.
Myostatin, a TGF-β family member produced primarily in skeletal muscle, is another key node. Myostatin is a potent inhibitor of muscle growth — it signals through ActRIIB and SMAD2/3 to suppress satellite cell activation and protein synthesis. In obesity, elevated systemic inflammation increases myostatin expression, compounding the catabolic drive. Adipose tissue also expresses myostatin, providing a direct adipose-to-muscle catabolic signal.
FGF21 (fibroblast growth factor 21) provides another link. FGF21 is secreted by the liver in response to fasting and metabolic stress and has beneficial effects on adipose metabolism. But in chronic obesity-associated inflammation, FGF21 signalling becomes dysregulated — muscle FGF21 resistance develops alongside the insulin resistance, impairing metabolic flexibility.
Lipotoxicity in muscle: ceramides and intramyocellular lipid
Beyond the inflammatory crosstalk, lipotoxicity in skeletal muscle is a critical mediator of the sarcopenic obesity phenotype. In obesity, the capacity of adipose tissue to safely store fatty acids is overwhelmed, and ectopic lipid accumulates in skeletal muscle as intramyocellular lipid (IMCL) — visible on MRS (magnetic resonance spectroscopy) as lipid droplets within muscle fibres.
The problem is not lipid per se — trained endurance athletes have high IMCL that they efficiently turn over during exercise. The problem is the lipid-derived signalling molecules that accumulate when lipid cannot be efficiently oxidised. Diacylglycerol (DAG) activates PKCθ (protein kinase C theta), which serine-phosphorylates IRS-1 (insulin receptor substrate 1) and impairs insulin signalling — contributing to insulin resistance in muscle. Ceramides — sphingolipids formed from the condensation of palmitoyl-CoA and serine — activate protein phosphatase 2A (PP2A) and block Akt phosphorylation, directly impeding the insulin → PI3K → Akt → AS160 → GLUT4 translocation pathway.
Impaired insulin signalling in muscle further impairs protein synthesis (insulin activates mTORC1 through Akt → TSC1/2 → Rheb), contributing to reduced anabolic response to amino acids. The lipid accumulation thus creates a triple failure: impaired glucose uptake, impaired protein synthesis, and continued inflammatory signalling — all of which drive sarcopenic progression.
What spirulina offers: the mechanistic case
Spirulina does not have dedicated clinical trials in sarcopenic obesity populations — this is a relatively recently defined clinical phenotype, and trials specifically targeting it with any intervention are sparse. The evidence for spirulina must be assembled from component mechanisms.
Anti-inflammatory effects: The chronic low-grade inflammation driving muscle catabolism in sarcopenic obesity involves NF-κB-dependent upregulation of atrogenes (muscle-specific E3 ligases). Phycocyanin is among the better-studied natural NF-κB inhibitors. Multiple studies have shown phycocyanin reduces NF-κB activation, TNF-α, IL-6, and IL-1β — the cytokines most directly linked to muscle protein degradation through the ubiquitin-proteasome pathway. If phycocyanin reduces the inflammatory driver of atrogin-1 and MuRF1 expression, it could partially attenuate muscle catabolism in the inflammatory environment of sarcopenic obesity.
Antioxidant protection of muscle: Skeletal muscle is highly susceptible to oxidative damage during both exercise and chronic inflammation. ROS generated by inflammatory macrophages and by impaired mitochondria in obese muscle damage contractile proteins, lipid membranes, and mitochondrial DNA. Spirulina provides beta-carotene (converted to vitamin A), vitamin E, and phycocyanin — antioxidants operating at different cellular compartments. Beta-carotene and vitamin E are lipid-soluble and protect membrane structures; phycocyanobilin is a potent aqueous antioxidant. A 2010 study by Hernandez-Corona and colleagues in elderly patients found spirulina supplementation reduced oxidative stress markers (TBARS) and increased antioxidant enzyme activity.
Amino acid composition and protein synthesis:Spirulina is approximately 60–70% protein by dry weight, with a reasonably complete essential amino acid profile. It contains all nine essential amino acids, including the branched-chain amino acids (BCAAs) leucine, isoleucine, and valine that are particularly important for muscle protein synthesis signalling. Leucine is a direct activator of mTORC1 through the Rag GTPase pathway — it is the amino acid whose rise in plasma most potently stimulates post-meal protein synthesis. Spirulina’s leucine content is approximately 3.5–4 g per 100 g dry weight — meaningful if consumed in grams-per-day doses alongside adequate total dietary protein.
The qualification is important: spirulina at typical supplemental doses of 3–10 g/day contributes 1.8–6 g protein, which is a small fraction of the 1.2–1.6 g/kg/day total dietary protein recommended for older adults with sarcopenia risk. Spirulina cannot substitute for adequate total protein intake — it can supplement it.
Animal data on lean mass: A 2018 study by Moradi and colleagues in Journal of the Science of Food and Agriculturefound that spirulina supplementation in high-fat diet-fed rats reduced body fat percentage while partially preserving lean mass compared to high-fat diet controls. The mechanism proposed involved AMPK activation reducing lipogenesis and improving fatty acid oxidation, which could indirectly reduce IMCL accumulation and improve the muscle metabolic environment.
Myostatin inhibition: a speculative but interesting angle
Some research groups have investigated whether natural compounds can influence myostatin signalling. Myostatin inhibition is pharmacologically established — the drug luspatercept (an ActRIIB ligand trap) is approved for anaemia in myelodysplastic syndromes and beta-thalassaemia partly through myostatin pathway effects. For sarcopenic obesity, reducing myostatin signalling would theoretically support muscle maintenance.
Spirulina’s direct effects on myostatin have not been well studied. There is indirect evidence that reduction in systemic inflammation (which drives myostatin overexpression) would secondarily lower myostatin. But this is hypothesis rather than established mechanism. Claims that spirulina directly inhibits myostatin cannot be supported by current evidence.
The irreplaceable role of exercise
Any honest discussion of sarcopenic obesity interventions must be direct about what spirulina cannot do. The most effective intervention for sarcopenic obesity — the one with the strongest and most consistent evidence — is progressive resistance exercise combined with adequate protein intake. Resistance training activates the mTORC1 pathway through mechanical overload and growth factor signalling independent of inflammation, stimulates satellite cell activation and muscle protein synthesis, and induces irisin secretion that promotes adipose browning.
Spirulina is an adjunct. In the context of a programme combining resistance exercise, adequate dietary protein (with attention to protein distribution across meals rather than bolus protein consumption), caloric moderation to address the obesity component, and management of the underlying metabolic drivers (insulin resistance, hypertension), spirulina’s anti-inflammatory, antioxidant, and modest protein contributions may provide additive benefit. Without the exercise foundation, the contribution of spirulina to muscle preservation is likely to be marginal.
The biology of sarcopenic obesity is now well enough understood to identify multiple intervention targets. Spirulina touches several of them. The honest summary is: plausible adjunct, insufficient as a primary intervention, no trials specifically in the sarcopenic obesity phenotype.